Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
5
×
clinical trials
life sciences
national blog main
national top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
fda
san francisco blog main
san francisco top stories
akcea therapeutics
alnylam pharmaceuticals
biotech
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
drugs
indiana blog main
indiana top stories
inotersen
national
new york
patisiran
raleigh-durham blog main
raleigh-durham top stories
regeneron pharmaceuticals
rna interference
seattle blog main
seattle top stories
tafamidis
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abbvie
acorda therapeutics
What
fda
5
×
patients
5
×
drug
ago
alnylam
approved
disease
friday
help
medicine
acorda
akcea
amyloidosis
approve
aren’t
attr
available
awaits
battle
bio
biological
cancer
cope
crossed
debilitating
decades
decision
developers
discovered
drugs
eisai
episodes
fingers
flags
gene
genetic
gets
higher
historic
imminent
Language
unset
Current search:
fda
×
patients
×
" boston top stories "
×
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Acorda Gets FDA Nod For New Parkinson’s Drug, But Rival Looms
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision